Challenges and trends in apomorphine drug delivery systems for the treatment of Parkinson's disease
Parkinson's disease (PD) is a chronic debilitating disease affecting approximately 1% of the population over the age of 60. The severity of PD is correlated to the degree of dopaminergic neuronal loss. Apomorphine has a similar chemical structure as the neurotransmitter dopamine and has been us...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2018-11-01
|
Series: | Asian Journal of Pharmaceutical Sciences |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1818087617306189 |
id |
doaj-53e04430893b45ce95f35101a19d6852 |
---|---|
record_format |
Article |
spelling |
doaj-53e04430893b45ce95f35101a19d68522020-11-25T02:46:16ZengElsevierAsian Journal of Pharmaceutical Sciences1818-08762018-11-01136507517Challenges and trends in apomorphine drug delivery systems for the treatment of Parkinson's diseaseNrupa Borkar0Huiling Mu1René Holm2Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, Copenhagen, 2100, Denmark; Corresponding author. Department of Pharmacy, University of Copenhagen, Universitetsparken 2, Copenhagen 2100, Denmark. Tel.: +45 71444174.Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, Copenhagen, 2100, DenmarkDrug Product Development, Janssen Research and Development, Johnson & Johnson, Turnhoutseweg 30, Beerse, 2340, BelgiumParkinson's disease (PD) is a chronic debilitating disease affecting approximately 1% of the population over the age of 60. The severity of PD is correlated to the degree of dopaminergic neuronal loss. Apomorphine has a similar chemical structure as the neurotransmitter dopamine and has been used for the treatment of advanced PD patients. In PD patients, apomorphine is normally administered subcutaneously with frequent injections because of the compound's extensive hepatic first-pass metabolism. There is, hence, a large unmet need for alternative administrative routes for apomorphine to improve patient compliance. The present review focuses on the research and development of alternative delivery of apomorphine, aiming to highlight the potential of non-invasive apomorphine therapy in PD, such as sublingual delivery and transdermal delivery. Keywords: Apomorphine, Drug delivery, Parkinson's disease, Alternative apomorphine therapy, Non-invasive delivery, Excipientshttp://www.sciencedirect.com/science/article/pii/S1818087617306189 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Nrupa Borkar Huiling Mu René Holm |
spellingShingle |
Nrupa Borkar Huiling Mu René Holm Challenges and trends in apomorphine drug delivery systems for the treatment of Parkinson's disease Asian Journal of Pharmaceutical Sciences |
author_facet |
Nrupa Borkar Huiling Mu René Holm |
author_sort |
Nrupa Borkar |
title |
Challenges and trends in apomorphine drug delivery systems for the treatment of Parkinson's disease |
title_short |
Challenges and trends in apomorphine drug delivery systems for the treatment of Parkinson's disease |
title_full |
Challenges and trends in apomorphine drug delivery systems for the treatment of Parkinson's disease |
title_fullStr |
Challenges and trends in apomorphine drug delivery systems for the treatment of Parkinson's disease |
title_full_unstemmed |
Challenges and trends in apomorphine drug delivery systems for the treatment of Parkinson's disease |
title_sort |
challenges and trends in apomorphine drug delivery systems for the treatment of parkinson's disease |
publisher |
Elsevier |
series |
Asian Journal of Pharmaceutical Sciences |
issn |
1818-0876 |
publishDate |
2018-11-01 |
description |
Parkinson's disease (PD) is a chronic debilitating disease affecting approximately 1% of the population over the age of 60. The severity of PD is correlated to the degree of dopaminergic neuronal loss. Apomorphine has a similar chemical structure as the neurotransmitter dopamine and has been used for the treatment of advanced PD patients. In PD patients, apomorphine is normally administered subcutaneously with frequent injections because of the compound's extensive hepatic first-pass metabolism. There is, hence, a large unmet need for alternative administrative routes for apomorphine to improve patient compliance. The present review focuses on the research and development of alternative delivery of apomorphine, aiming to highlight the potential of non-invasive apomorphine therapy in PD, such as sublingual delivery and transdermal delivery. Keywords: Apomorphine, Drug delivery, Parkinson's disease, Alternative apomorphine therapy, Non-invasive delivery, Excipients |
url |
http://www.sciencedirect.com/science/article/pii/S1818087617306189 |
work_keys_str_mv |
AT nrupaborkar challengesandtrendsinapomorphinedrugdeliverysystemsforthetreatmentofparkinsonsdisease AT huilingmu challengesandtrendsinapomorphinedrugdeliverysystemsforthetreatmentofparkinsonsdisease AT reneholm challengesandtrendsinapomorphinedrugdeliverysystemsforthetreatmentofparkinsonsdisease |
_version_ |
1724759537889574912 |